🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to scientists.

A Global Public Health Issue

Cases of gonorrhoea are increasing globally, with data suggesting more than 82 million new cases each year. Particularly high rates are reported in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the reality of growing infection rates, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Health officials are increasingly worried about the rise in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". Ongoing monitoring found that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Secure Authorization

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists anticipate that specific application of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GSK, gained clearance in concurrent days. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin stemmed from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to bring it to fruition.

“This milestone signifies a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Research Study Outcomes and Global Access

Based on data released by a major medical journal, zoliflodacin successfully treated over nine in ten of cases of the STI. This puts it on an equal footing with the current standard treatment, which combines two antibiotics. The research involved over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the ability to license and sell the drug in many low-income and middle-income countries.

Medical professionals on the front lines have expressed positive views. Access to a one-pill regimen like this is hailed as a "revolutionary step" for gonorrhoea control. This is considered crucial to lessen the impact of the disease for individuals and to prevent the spread of extremely resistant gonorrhoea globally.